Full Text View
Tabular View
No Study Results Posted
Related Studies
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
This study has been completed.
Study NCT00449748   Information provided by M.D. Anderson Cancer Center
First Received: March 19, 2007   Last Updated: October 23, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Mastocytosis
Additional conditions recognized in this trial
Mastocytoma
Mastocytosis
Mastocytosis, Systemic
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Skin Diseases
Interventions listed in this trial
RAD001
Additional drug interventions recognized in this trial
Everolimus
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
M.D. Anderson Cancer Center
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services